Skip to main content
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. — Investor Relations & Filings

Ticker · PYXS ISIN · US7473241013 US Manufacturing
Open in API
Filings indexed 308 across all filing types
Latest filing 2023-06-29 Regulatory Filings
Country US United States of America
Listing US PYXS

About Pyxis Oncology, Inc.

https://pyxisoncology.com/

Pyxis Oncology, Inc. is a clinical-stage company focused on developing next-generation therapeutics for difficult-to-treat cancers. The company's differentiated portfolio of clinical assets is centered on two primary modalities: antibody-drug conjugates (ADCs) and immuno-oncology (IO). Its ADC technology platform is designed to deliver potent cancer-killing agents directly to tumor cells for enhanced safety and efficacy. The immuno-oncology programs utilize monoclonal antibodies (mAbs) to mobilize the body's immune system to attack cancer cells by blocking tumor defense mechanisms and overcoming immune suppression. Pyxis Oncology is advancing its product candidates as both monotherapies and in combination with other therapies to improve outcomes for patients with solid tumors.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date for a Registration Statement on Form S-4. It is a correspondence related to a regulatory filing process, specifically about the timing of the effectiveness of a registration statement for securities. The document is short (1482 characters) and does not contain financial data or detailed report content. It is not the registration statement itself but a procedural request related to it. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and correspondence that do not fit other categories.
2023-06-29 English
FORM S-4/A
Merger & Acquisition Classification · 100% confidence The document is a Form S-4 Registration Statement filed with the SEC, which is used for securities registration in connection with mergers and acquisitions. It includes a proxy statement/prospectus related to a merger between Pyxis Oncology, Inc. and Apexigen, Inc. The text discusses the merger agreement, voting proposals for stockholders, and details about the merger transaction. This type of filing is specifically related to merger and acquisition activity, not a general annual report, earnings release, or other categories. Therefore, the appropriate classification is Merger & Acquisition (MA). The document length and content confirm it is the actual filing, not just an announcement or proxy solicitation alone.
2023-06-29 English
Regulatory Filings 2023
Regulatory Filings
2023-06-16 English
Regulatory Filings 2023
Regulatory Filings
2023-06-15 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated June 13, 2023, reporting the submission of matters to a vote of security holders at the company's Annual Meeting. It details the voting results for director elections and ratification of the independent auditor. The content focuses on official voting results from the shareholder meeting, not the meeting materials or the full annual report. The key section is 'Item 5.07. Submission of Matters to a Vote of Security Holders,' which matches the description of Declaration of Voting Results & Voting Rights Announcements. The document length is 4566 characters, which is sufficient to include detailed voting results, not just a brief announcement. Therefore, the correct classification is DVA (Declaration of Voting Results & Voting Rights Announcements).
2023-06-13 English
Regulatory Filings 2023
Regulatory Filings
2023-06-08 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.